|Bid||90.75 x 1000|
|Ask||93.75 x 1200|
|Day's range||91.70 - 103.57|
|52-week range||91.70 - 331.68|
|Beta (5Y monthly)||1.16|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2022 - 04 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||270.00|
Dr. Taison Bell, Assistant Professor of Medicine at the University of Virginia, joins Yahoo Finance Live to discuss Virginia getting rid of its mask mandate for schools, the Omicron variant, and coronavirus vaccinations.
Novavax has resolved manufacturing issues and gained authorization in more than 30 countries. Novavax may be on its way to generating billions of dollars in revenue. With all of this good news, could Novavax stock go parabolic?
Dr. Robert G. Lahita MD, PhD, Director of the Institute for Autoimmune and Rheumatic Disease at Saint Joseph Health and author of Immunity Strong, joins Yahoo Finance Live to discuss the latest information on COVID-19 booster vaccinations, transmissibility, and the pressures felt by hospitals in remote regions.